MedTrace Logo

Post-Market Evaluation of the EVO ICL

NCT05538754 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2026-03-05

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).

Conditions

  • Myopic Astigmatism
  • Myopia

Interventions

DEVICE

EVO ICL

The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.

Sponsors & Collaborators

  • Staar Surgical Company

    lead INDUSTRY

Principal Investigators

  • Joanne Egamino, PhD · Staar Surgical Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-23
Primary Completion
2023-09-21
Completion
2023-10-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05538754 on ClinicalTrials.gov